503B Compounding Pharmacy

GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.

As compounded medications gain popularity amid drug shortages, concerns about safety, quality, and regulation have intensified, making Pharmacy Compounding Accreditation Board (PCAB) accreditation a safeguard for consistency, oversight, and public trust in compounding pharmacy practices.

Recognizing pharmacy technicians as non-pharmacist preceptors can provide an opportunity for professional development while encouraging technicians to practice at the top of their education and training activities.

Hospital compounding is gaining renewed attention amid drug shortages, regulatory changes, and labor challenges, prompting pharmacies to leverage advanced technology for safer, more efficient, and compliant medication preparation.

Mark Mulvahill, MBA, MSc, discusses the importance of microbial preservation and reference materials in pharmaceutical manufacturing and compounding pharmacies, highlighting their role in contamination control, regulatory compliance, and enhancing microbiological testing reliability.

Martha Rumore, PharmD, Esq, discusses the legal and regulatory complexities surrounding tirzepatide compounding following FDA’s removal of the drug from the shortage list, which prompted a lawsuit and led to ongoing uncertainty for 503A and 503B facilities regarding enforcement discretion and future compounding restrictions.

Pharmacists can educate patients about how to recognize unsafe online sources of medications and ensure patients are properly educate on how to administer their medications.

The lawsuit alleges that the action was taken without the required notice and disputes the agency’s warning of “localized supply disruption,” while calling for more transparency.

A review of the requirements for pharmacies considering ordering compounds from a 503B facility.

Although robotics can be instrumental in assuring sterility and reducing the overall number of potential hazardous drug exposure events, certain tasks require vigilant oversight.

The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).

By combining the administration of psychedelic compounds with therapeutic support, ketamine-assisted therapy is proving remarkable efficacy in treating mental health conditions.

Implementing these standards can be logistically challenging.

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

An increased demand for methylphenidate products as a result of Adderall shortages has led to a short supply of some popular products, including Ritalin and Concerta.

For many patients with C diff, the experience of medical gaslighting is a common one because many health care providers lack education and familiarity with the disease.

Drug shortages have led to increased use of compounding pharmacy.

Analyzing the patent and trademark challenges faced by 503A compounding pharmacies.

When considering outsourcing, pharmacies should use a multistakeholder team to weigh pros and cons.

Illegal online sellers threaten the health, privacy, and security of patients by failing to comply with the laws of the jurisdiction in which they are located, or the jurisdiction in which they are selling their medicines.

Pharmacists will play a growing role in the use of biosimilars and guiding patients through the switching process.

The FDA’s temporary Guidance for 503A compounding of shortage drugs was meant to be temporary and withdrawn once COVID-19 ended.

Part 1 of this 2-part series examines USP <797> and <795> revisions for sterile and nonsterile compounding, veterinary compounding, FDA inspections of 503A pharmacies, and the interstate distribution of compounded prescriptions post Wellness Pharmacy v. FDA.

This action is of considerable significance as it supports the regulation of cannabis and cannabis-derived products as medicine under the Federal Food, Drug and Cosmetic Act.

Farah Towfic, PharmD, MBA, RPh, director, CEO Operations, US Pharmacopeia, discusses some of the primary topics impacting pharmacists’ delivery of care and quality this year.